FlexMedical Solutions partners with Lepzi on Gates Foundation–funded Preeclampsia Diagnostic Project
FlexMedical Solutions is proud to announce its role as a key partner in the delivery of a Gates Foundation grant awarded to Lepzi to advance next-generation diagnostics for preeclampsia.
As part of this initiative, FlexMedical is collaborating closely with Lepzi on the development of a class-leading PLGF assay, a critical component of an innovative dual-biomarker (PLGF + sFlt-1) point-of-care test designed to aid in the diagnosis of pregnant women at risk of preeclampsia.
The project aims to deliver accurate, affordable, and accessible testing solutions, particularly for use in low- and middle-income countries, where reliable diagnostics can have the greatest impact on maternal and neonatal health.
This collaboration highlights FlexMedical’s expertise in assay development and point-of-care technology and reinforces the company’s commitment to creating a healthier tomorrow, through innovative diagnostic solutions.